What do systematic reviews say?

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 429 participants
  Very low

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 429 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 756 participants
  Moderate

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 756 participants
  Moderate

Intervention not reported

• Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 327 participants
  Moderate

Paracetamol (single administration, any dose) vs placebo

Paracetamol (single administration, any dose) may leads to higher adequate pain relief as reported by women compared with placebo (low certainty).

• Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
  RR 2.14 [1.59, 2.89]
  10 studies · 1279 participants
  Low

Paracetamol (single administration, any dose) vs placebo

Paracetamol (single administration, any dose) may leads to lower additional pain relief compared with placebo (low certainty).

• Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
  RR 0.34 [0.21, 0.55]
  8 studies · 1132 participants
  Low

Paracetamol (single administration, any dose) vs placebo

Paracetamol (single administration, any dose) showed no clear difference in maternal drug adverse effects (nausea) compared with placebo (low certainty).

• Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
  RR 0.18 [0.01, 3.66]
  1 study · 232 participants
  Low

Paracetamol (single administration, any dose) vs placebo

Paracetamol (single administration, any dose) showed no clear difference in maternal drug adverse effects (sleepiness) compared with placebo (low certainty).

• Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
  RR 0.89 [0.18, 4.3]
  1 study · 232 participants
  Low

Paracetamol (single administration, any dose) vs placebo

The review found no eligible studies for this question.

• Paracetamol/acetaminophen (single administration) for perineal pain in the early postpartum period 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine probably leads to higher hypothyroidism compared with radioiodine (moderate certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 2.53 [1.52, 4.2]
  6 studies · 321 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine showed no clear difference in adverse events compared with radioiodine (low certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 1.24 [0.94, 1.63]
  6 studies · 321 participants
  Low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 268 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

The review found no eligible studies for this question.

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  147 studies · 52144 participants
  Very low

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  56 studies · 20452 participants
  Very low

Intervention not reported

• Abdominal ultrasound and alpha‐foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  39 studies · 18792 participants
  Very low